Despite the fact that the immune system plays a significant role in both diseases, DMARDs effective in the treatment of RA, including tumor necrosis factor α (TNFα) and interleukin-1 (IL-1) inhibitors, have so far proven unsuccessful in slowing disease progression and clinical deterioration of OA patients. The gene discussed is TNF; the disease is rheumatoid arthritis.